BACKGROUND: The safety and efficacy of venous thromboembolism (VTE) treatment in patients with acute leukemia (AL) are not well
Abstract
BACKGROUND: The safety and efficacy of venous thromboembolism (VTE) treatment in patients with acute leukemia (AL) are not well understood and the optimal treatment strategy is unclear.
METHODS: We conducted a systematic review of the literature aiming to identify observational studies and randomized trials describing treatment of VTE in the setting of AL including, acute myeloid leukemia (AML), acute promyelocytic leukemia (APL), and acute lymphoblastic leukemia (ALL). Due to the heterogeneity of findings, no meta-analysis was attempted.
RESULTS: A total of 13 observational studies (11 cohorts and 2 case-control) totaling 5359 participants were included. The number of patients with VTE among the total population was 304 (5.7%; 95% CI 5.1-6.3). In patients with VTE, 221 patients received treatment with anticoagulation using either of low-molecular-weight heparin, unfractionated heparin, and/or vitamin K antagonists. Most studies adjusted the anticoagulant dose based on platelet count. The reported recurrence rate ranged from 0 to 29% among different studies and varied according to the duration of anticoagulant treatment and follow up. Bleeding events were not uniformly reported but the total number was low among anti-coagulated patients.
CONCLUSION: There is a significant lack of data in this area with a high degree of heterogeneity in the choice of anticoagulant, dose adjustments for thrombocytopenia, and duration of anticoagulation. Further studies are required to develop guidelines and suggestions for treatment of VTE in AL.
PMID: 30921533 [PubMed - indexed for MEDLINE]
14:52
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:52
In reply to this message
pubmed: caandvteortroorpul
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/https:--linkinghub.elsevier.com-ihub-images-PubMedLink.gif Related Articles
Orthotopic liver transplantation in a patient receiving apixaban for portal vein thrombosis.
J Clin Anesth. 2019 Sep;56:41-42
Authors: Dibiasi C, Wiegele M, Gratz J
PMID: 30684925 [PubMed - indexed for MEDLINE]
14:52
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
14:52
In reply to this message
pubmed: caandvteortroorpul
The Challenge of Thromboprophylaxis in Cancer Patients-Balancing the Thrombotic and Bleeding Risks.
//www.ncbi.nlm.nih.gov/corehtml/query/egifs/http:--www.thieme.de-classic-images-tc-logo_tc.jpg Related Articles
The Challenge of Thromboprophylaxis in Cancer Patients-Balancing the Thrombotic and Bleeding Risks.
Thromb Haemost. 2018 08;118(8):1347-1349
Authors: Potpara TS, Poposka L
PMID: 30060254 [PubMed - indexed for MEDLINE]
4 March 2020
12:04
Cancer & Heart (Cardio-Oncology, Cardiotoxicity, TEV)
Photo
Not included, change data exporting settings to download.
256×256, 6.0 KB
12:04
In reply to this message
pubmed: caandvteortroorpul
Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score.
Related Articles
Prognosis in patients with cancer-associated venous thromboembolism: Comparison of the RIETE-VTE and modified Ottawa score.
J Thromb Haemost. 2020 Mar 02;:
Authors: Pfaundler N, Limacher A, Stalder O, Méan M, Rodondi N, Baumgartner C, Aujesky D
Comments
Post a Comment
اكتب تعليق حول الموضوع